A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
NCT06855823
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Interventions
DRUG:
Golicitinib combined with Pomadomide
Sponsor
Sun Yat-sen University